Introduction
We previously reported a novel interstitial deletion of chromosome 14 involving the immunoglobulin heavy chain locus (IGH) (del(14q/IGH)) in 27 cases of B-cell malignancies, including chronic lymphocytic leukemia (CLL), low grade lymphoma and myeloma. 1 We initially hypothesized that del(14q/IGH) might operate like classical IGH translocations (e.g., t(8;14)(q24;q32)/ IGH-CMYC) and deregulate unknown 14q proto-oncogenes by their juxtaposition with the E enhancer of IGH. However, extensive transcriptomic studies failed to identify a constantly overexpressed gene flanking the proximal breakpoint of the recurrent del(14)(q24.13q32.33). 1 Alternatively, like many other cancer-related deletions, del(14q/IGH) may flag the existence of a tumor suppressor gene (TSG) located at 14qter. It is noteworthy in this regard, that loss of 14q sequences has been recurrently observed in several solid tumor types including gastrointestinal stromal tumors, carcinomas of the bladder, ovary, intestine and kidney, and meningiomas. 2 The minimal commonly deleted region (MDR) established in the reported B-cell malignancies (later referred as index cases) covers a ~10.5 Mb region at 14q32.13q32.33. Interestingly, the MDR encompasses the DLK1-GTL2 imprinted domain ( Fig. 1) that houses paternally expressed protein-coding genes (DLK1, RTL1/ PEG11 and DIO3), and maternally expressed long and short noncoding RNA genes [MEG3/GTL2, RTL1as, MEG8, 41 C/D Box small nucleolar (sno) RNAs and 52 microRNAs (miRNAs)]. 3, 4 Imprinting of the DLK1-GTL2 domain is controlled by the intergenic differentially methylated region (IG-DMR), located in the DLK1-GTL2 intergenic region and undergoing methylation in the male but not female germline (Fig. 1) . 5 Epigenetic alterations in the IG-DMR domain, not associated with LOH at 14q32.2, has been demonstrated in a subset of neuroblastoma tumors, phaeochromocytoma and Wilms tumors. 6 The DLK1 gene involved in embryonic growth and normal hematopoiesis, 7 was found to be repressed in renal cell carcinoma 8 and highly expressed in neuroblastoma, small-cell lung carcinoma, myelodysplastic syndrome and acute myeloid leukemia. 7 The MEG3/GTL2 gene suppresses cancer cell growth in vitro, stimulates p53-mediated transactivation and its expression is selectively lost in pituitary adenomas. 9, 10 The function of 14q32.2 miRNAs is largely unknown. These genes are highly expressed in brain 11 and likely involved in a regulation of the cell cycle and immune response. 12 It has been suggested that at least two of them, mir-127 and mir-370, targeting BCL6 and MAP3K8, respectively, contribute to tumorigenesis. 13, 14 All these findings, together with a postulated role of miRNAs as TSGs in human cancers in general, 15, 16 and in CLL in particular, [17] [18] [19] prompted us to hypothesize that a putative TSG associated with del(14q/IGH), if located in the DLK1-GTL2 imprinted domain, might be inactivated by a single genetic hit, e.g., by a targeted deletion of its functional expressed allele. Such 'non-classical' mechanisms of TSG inactivation affecting Leukemias/lymphomas with IGH-involving del(14q) 1 commonly lose the DLK1-GTL2 imprinted domain that comprises several paternally and maternally expressed genes, including a cluster of microRNAs. Given that deletion of this region could lead to inactivation of a monoallelically expressed tumor suppressor gene, our study aimed at determination of the parental origin of del(14q/IGH DLK1/GTL2 intergenic differentially methylated region allowed us to determine the parental origin of del(14q/IGH) in 9/20 analyzed cases. In six cases del(14q/ IGH a TSG/anti-oncomir located in the imprinted region is systematically inactivated by a targeted deletion of its functional allele.
a ~0.85 Kb segment encompassing the DLK1-GTL2 IG-DMR, (2) identified the deleted allele on the basis of the resulting allelic imbalance in the sample (comprising both neoplastic and normal cells), and (3) determined the parental origin of the deleted allele based on the methylation status of the IG-DMR. The tested hypotheses and design of the study are schematically shown in Figure 1A and B.
We validated our ability to discriminate the paternal and maternal 14q homologues on the basis of differential IG-DMR methylation using leukocyte DNA from a healthy trio (father, mother and child). Sequencing of the IG-DMR region (Fig. 1Bb) revealed two SNPs (corresponding respectively to rs1884538 and rs1884539 in the NCBI dbSNP databank;
22 S1 and S3 in Fig. 1Bd ) for which the child was heterozygous (A/G), on the strand selected for bisulfite sequencing ( Fig. 2A) . Analysis of individual sequence reads indicated that the genotypes of the father, mother and child were respectively GA/AA, GG/AA and AA/ GG. Thus, the child's GG haplotype was inherited from the mother while the AA haplotype originated from the father. The ratio of haplotypes amongst sequenced clones did not depart significantly from unity for any of the three individuals. Bisulfite treatment of the trios' DNA, strand-specific PCR amplification of the IG-DMR/ SNPs containing region, cloning and sequencing of at least 21 clones per individual yielded the results shown in Figure 2C . The bisulfite conversion of non CpG cytosines was 98% on average and comparable across haplotypes, confirming the efficacy of the bisulfite treatment. The two haplotypes of each of the three individuals exhibited a completely distinct methylation profile: the CpG methylation rate averaged 97% for one haplotype, and 24% for the other ( Table 1) . In the child, the hypermethylated haplotype was the paternal AA haplotype, while the maternal GG allele was hypomethylated, hence confirming previous findings 5 and the feasibility of the proposed approach.
We sequenced the corresponding IG-DMR region from tumor material of the 20 index cases. Nine patients were found to be heterozygous for at least one of three A-G transitions corresponding to the previously described rs1884538 and rs1884539, 22 plus one novel SNP (chr14 position 100,347,524; S2 in Figs. 1B; and 2B). Five additional patients were heterozygous for another novel SNP (chr14: position 100,347,641). As this SNP corresponds to imprinted growth-inhibitory genes, have been reported in human cancer. 20, 21 In other words, our working hypothesis states that if one of the imprinted genes in the DLK1-GTL2 domain, whether normally paternally or maternally expressed, is the TSG affected by del(14q/IGH), this would result in the preferential loss of either the paternal homologue (paternally expressed TSG, e.g., DLK1, RTL1/PEG11 and DIO3) or the maternal homologue (maternally expressed TSG, e.g., MEG3/GTL2, MEG8 or the small snoRNAs and/or miRNAs). To investigate a non-random choice of the deleted chromosome with regards to parental origin, we attempted to determine the parental origin of the chromosome 14 homologue affected by del(14q/IGH) in our index cases on the basis of their methylation status.
Results and Discussion
To assess the parental origin of the chromosome affected by del(14q/IGH) in the 20 index cases (in the absence of parental DNA samples), we (1) searched for heterozygous SNPs in Figure 1A . expressed TSG. The deletion of the maternal allele (red) in the tumor cells would lead to complete absence of TSG transcripts as the paternal copy (blue) is epigenetically silenced. As available samples allelic imbalance for heterozygous SNPs. The parental origin of the deleted allele can be determined on the basis of the distinct methylation status of the paternal and maternal allele at the DLK1-GTL2 IG-DMR. The second (b) assumes the existence of a paternally expressed TSG and its deletion in tumors.
a C-T transition on the strand subjected to methylation analysis, these patients, as well as the remaining six cases without any heterozygous variant, were not considered for further analysis. We assessed allelic imbalance for the nine retained cases by examining the sequence traces with the PeakPicker software. 23 Estimates of allelic ratios (minor/major allele) in tumors ranged from 0.10 to 0.74 ( Table 1 ). In comparison, estimates of allelic ratios in genomic DNA of the control trio ranged from 0.80 to 0.99. For each tumor, the minor allele was assumed to correspond to the deleted allele. We then compared the IG-DMR methylation status of the corresponding alleles by bisulfite analysis. We sequenced at least 19 clones per individual (range: 19-53). The allelic ratios in the sequenced clones were in agreement with the allelic ratios in genomic DNA estimated with the PeakPicker software. The conversion ratio of non CpG cytosines in the index cases averaged 98%. The average CpG methylation rate of the most methylated allele ranged from 82% to 100%, and for the less methylated allele from 25% to 74%. Assuming that the most highly methylated allele always corresponded to the paternal allele, we found that del(14q/ IGH) affected the paternal allele in six cases (#2, 3, 5, 6, 7 and 9) and the maternal allele in the three remaining cases (#1, 4 and 8) ( Fig. 2D and E; online Suppl. Fig. 1 ). There was no correlation between the parental origin of del(14q/IGH) and type (recurrent/non-recurrent) of del(14q/ IGH) ( Table 1) . Taken together, these findings do not support the systematic loss of either the paternal or maternal allele in tumors, but rather a random choice of deleted chromosome with regards to parental origin. level was markedly increased from an average of 24% (range: 13-37%) in controls to an average of 65% (range: 55-74%) in the tumor samples. When the paternal allele was retained, its methylation level tended to be reduced from an average of Intriguingly, the methylation status of the non-deleted allele, whether paternal or maternal, was altered when compared to the corresponding homologue in disomic controls (Online Suppl. Fig. 2) . When the maternal allele was retained, its methylation the existence of a trans-acting sensing mechanism between homologues. Noteworthy is that evidence for a trans-interaction between the paternal and maternal homologue affecting the methylation status of the DLK1-GTL2 region has been described before. 24 In summary, this study does not support the preferential deletion of a specific allele, whether the paternal or the maternal one, in leukemia/lymphoma cases with the del(14q/IGH). At first glance, this suggests that imprinted genes in the DLK1-GTL2 domain are not directly involved as TSG in the pathogenesis of these tumors. Note that our results do not preclude that imprinted genes from the DLK1-GTL2 domain act as TSG in 97% (range: 95-98%) in controls to an average of 83% (range: 82-84%) in the tumor material. In contrast, the methylation status of the allele deleted in the tumor samples (i.e., still present in contaminating normal cells) was identical to that of controls: 31% (range: 25-41%) for the maternal allele and 97% (range: 92-100%) for the paternal allele. One explanation for this finding is that tumor samples obviously differ from whole blood (controls) with regards to cell type composition. Thus the increased methylation rate of the maternal allele and decreased methylation of the paternal allele could be a property of lymphocytes. Alternatively, the loss of a homologue might affect the methylation status of the retained one. This would imply study and to continue further molecular investigations of this novel intriguing aberration, collection of well-documented cases with del(14q/IGH) is needed.
Material and Methods
Samples. Twenty leukemia/lymphoma cases with del(14q/IGH) were included in this study. Genomic DNA was isolated from lymph nodes (seven cases), peripheral blood (four cases) and bone marrow samples (nine cases) showing a various involvement (15-70%) by neoplastic cells. The study was approved by the Ethics Committee of our Institution. Single nucleotide polymorphism (SNP) study. The 14q32.2 regions subjected for SNP genotyping were amplified using the following PCR primers: GAA CTG GGG CAT TGT TTA CAC C (aF), AAG TTG CCT GAG GAC CGT AGA TAA (aR), GGT ACT GTA ACT GGC CAC AAT G (bF), GTT TAT GAT AGC TCA GGG TTG C (bR) (Fig. 1B) . PCR was carried out using Gold Taq DNA polymerase (Applied Biosystems, Foster City, CA) and the following PCR conditions: 95°C for 10 min followed by 30 cycles of 94°C for 30 seconds, 60°C (region A) or 58°C (region B) for 30 seconds, 72°C for 40 seconds and a final extension of 72°C for 7 minutes. PCR products were purified using a MultiScreen R PCR 96 Plate (Millipore, Billerica, MA) other types of tumor. It is noteworthy, however, that to the best of our knowledge no increase in susceptibility to cancer has been reported in patients with either paternal or maternal uniparental disomies encompassing the DLK1-GTL2 domain (in contrast with e.g., the Beckwith-Wiedemann syndrome underlied by an aberrant imprinting of the 11p15.5 region 25 ). However, we provided intriguing evidence for epigenetic alterations of the retained chromosome. In particular, we observed a marked increase in the methylation level of the IG-DMR of the non-deleted maternal chromosome. Thus, the maternal chromosome may adopt a paternal epigenotype on deletion of the paternal chromosome. If true, this implies that loss of either the maternal or paternal chromosome in effect leads to perturbed expression of maternally expressed genes, which may contribute to pathogenesis of these tumors. Detailed analysis of the expression pattern of genes from the DLK1-GTL2 domain in tumors is needed to address this hypothesis.
Alternatively, the recurrent del(14q/IGH) deletion flags a molecular event independent of the imprinted DLK1-GTL2 domain whether involving a gain or loss of function event. Given that the currently established MDR, expected to harbour a postulated TSG, covers ~10.5 Mb and encompasses hundreds of coding and non-coding genes, its identification will be challenging. To overcome material restrictions resulting from a retrospective and directly sequenced using BigDye terminator cycle sequencing kit v3.1 (Applied Biosystems) on ABI 3730 DNA analyzer. The allelic ratios of informative SNPs were determined using the PeakPicker software version 0.5.
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Methylation analysis of the DLK1-GTL2 IG-DMR using bisulfite sequencing. Genomic DNA (0.5 g) was treated with sodium bisulfite using the EZ DNA Methylation-Gold Kit TM (Zymo Research Corp., Orange, CA) according to the manufacturer's protocol. The bisulfite modified DNA was PCR amplified using 40 cycles of 95°C for 5 seconds, 60°C for 2 minutes, 72°C for 45 seconds and a final extension of 72°C for 10 minutes as described above. Non-methylation-specific primers amplifying both methylated and unmethylated 14q32.2 alleles were designed as follows: bsF-TTA GGT TGG AAT TGT TAA GAG TTT GTG and bsR-CAC CAT TAA CCT CCA ACA AAA AT. After subcloning of the PCR products with the TOPO TA cloning kit (Invitrogen, Carlsbad, CA), randomly selected individual bacterial clones were colony PCR amplified and subjected to gel electrophoresis. Amplification products of the expected size from at least 19 individual bacterial clones per case were directly sequenced as described above. Clones exhibiting exactly the same C to T conversion pattern and/or PCR-introduced substitutions were assumed to derive from the same molecule and were hence only considered once in subsequent analyses.
